Amgen's senior vice president of global development recently gave a presentation at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference in Boston.
Dr. Elliott Levy presented at the event, according to a company announcement. Remote viewers who were not able to attend the live event can access the session at the Investor section of Amgen’s website. Additionally, the presentation will be available for a minimum of 90 days afterward.
Levy has served in his current position for the past three years and provides strategic guidance on behalf of Amgen as a board member of TransCelerate BioPharma Inc. He oversees the clinical development of Amgen’s pipeline.
He worked at Bristol-Myers Squibb in Princeton, New Jersey, for 17 years, according to his bio on the TransCelerate website. Levy received his medical degree from the Yale University School of Medicine.
The Evercore ISI 2017 Biopharma Catalyst/Deep Dive conference also featured representatives from diverse biopharmaceutical industry businesses.
Amgen develops treatments for serious medical conditions by using sophisticated genetics “to unravel the complexities of disease and understand the fundamentals of human biology,” specializing in unmet needs, on a global scale, according to the announcement.
